Enjaymo Marks Latest Milestone In Sanofi’s Blood Disorder Effort
Executive Summary
The company plans to draw on experience with other rare blood disorder drug launches, but pointed to some differences in the market for cold agglutinin disease.
You may also be interested in...
AstraZeneca/Sanofi’s RSV Shot Among 13 Hopefuls Awaiting EU Verdict
Its crunch time for sponsors of more than a dozen products as the EMA meets to adopt opinions on several marketing authorization applications.
Star And Portfolio Firm Electra Roll Out With Focus On Rare Immunologic Disease
Star will employ a hub-and-spoke model to launch portfolio companies focused on specific biological areas. The first company, Electra, will emphasize unmet medical needs and therapies that can address multiple diseases.
Sanofi Exit From Sickle Cell Gene Therapy Leaves Sangamo With Difficult Decision
Sanofi’s decision is influenced by its own in-house options, but also by the growing competition in sickle cell gene therapy.